Hisashi Kosaka

Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population

Andrea Casadei‐Gardini, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2022 · 123 citations · Full text

Oncology, Hepatology, Medicine +8

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child‐Pugh class A or B liver function in real‐world clinical practice

Takaaki Tanaka, Atsushi Hiraoka, Toshifumi Tada et al. · Hepatology Research · 2022 · 77 citations · Full text

Prognostic impact of C-reactive protein and alpha-fetoprotein in immunotherapy score in hepatocellular carcinoma patients treated with atezolizumab plus bevacizumab: a multicenter retrospective study

Takeshi Hatanaka, Satoru Kakizaki, Atsushi Hiraoka et al. · Hepatology International · 2022 · 77 citations

C-reactive Protein, Hepatology, Hepatocellular Carcinoma Patients +10

Sequential therapies after atezolizumab plus bevacizumab or lenvatinib first-line treatments in hepatocellular carcinoma patients

Mara Persano, Margherita Rimini, Toshifumi Tada et al. · European Journal of Cancer · 2023 · 50 citations · Full text

Multivariate logistic regression analysis for prediction of clinically relevant pancreatic fistula in the early phase after pancreaticoduodenectomy

Hisashi Kosaka, Nobukazu Kuroda, Kazuhiro Suzumura et al. · Journal of Hepato-Biliary-Pancreatic Sciences · 2013 · 48 citations